We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mesenchymal Stem Cells and Myocardial Ischemia (MESAMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01076920
Recruitment Status : Completed
First Posted : February 26, 2010
Last Update Posted : September 19, 2014
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Ischemic cardiomyopathies are a leading cause of death in both men and women. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly, that area of the heart can suffer permanent damage. While recovery from a heart attack can be managed through medications and lifestyle changes, these treatments can not reverse the all damage to the heart. Current research is focusing on the development of cell-based therapies using stem cells to repair organs that have been irreversibly damaged by disease. A specific form of stem cells, called adult mesenchymal stem cells (MSCs), has shown promise for heart repair. This study will evaluate the safety of injecting MSCs directly into the heart to repair and restore heart function in people who have had a heart attack and who have chronic myocardial ischemia with heart failure.

Condition or disease Intervention/treatment Phase
Chronic Myocardial Ischemia Left Ventricular Dysfunction Genetic: Mesenchymal stem cells Phase 1 Phase 2

Detailed Description:
Mesenchymal stem cells from the bone marrow can differentiate into endothelial cells and participate in the development of new blood vessels in ischemic tissue. The aim of the study is in a phase I safety study to evaluate the clinical effect of autologous mesenchymal stem cell therapy in patients with severe chronic myocardial ischemia.10 patients with reversible ischemia on a SPECT will be treated with direct intramyocardial injections of autologous isolated and expanded mesenchymal stem cells.Clinical and objective evaluations will be performed at baseline and during 24 months follow-up.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy
Study Start Date : October 2009
Primary Completion Date : February 2014
Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Intervention arm Genetic: Mesenchymal stem cells
60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)


Outcome Measures

Primary Outcome Measures :
  1. Evaluate safety and feasibility of transendocardial injection using the NogaStar XP Mapping Catheter with the MyostarTM Left Ventricular Injection Catheter of autologous MSC in subjects with chronic myocardial ischemia and left ventricular dysfunction [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Change from baseline in SF-36, VO2max, 6 min walk test, and the NYHA, CCS Classifications Effect related to cardiac function [ Time Frame: 30 days to 2 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 to 75
  2. Male or female
  3. NYHA (Heart failure) Class II-IV or Angina pectoris CCS Class III or IV or symptoms consistent with)
  4. Chronic coronary artery disease with left ventricular function below 35%
  5. Stable medical therapy for at least one month
  6. Reversible perfusion defects by SPECT
  7. Not a candidate for coronary artery by-pass surgery due to poor targets or small vessels and not a candidate for percutaneous intervention due to small vessels or unreachable coronary lesions due to complicated anatomy
  8. Implantable Cardiovertor Defibrillator

Exclusion Criteria:

  1. Acute coronary syndrome, revascularization (PCI or CABG), or cardiac resynchronization during the last 3 months
  2. Sustained ventricular
  3. Further revascularization planned for the next 30 days.
  4. Chronic atrial fibrillation.
  5. A wall thickness in the target region <8 mm as determined by 2D echocardiography (the target region is defined at the time of NOGA® mapping).
  6. An LV thrombus.
  7. Severe peripheral vascular disease precluding femoral artery access as determined at time of original catheterization.
  8. Aortic stenosis as determined as valve area less than 1 cm2 that prohibits catheter access to the LV.
  9. Human immunodeficiency virus (HIV1-2), HTLV-1 and 2.
  10. An active uncontrolled infection.
  11. A prosthetic aortic valve.
  12. A current or prior history within the last 3 years of neoplasm (excluding basal cell) and/or any active neoplasm within the last 24 months.
  13. Pregnancy or breastfeeding.
  14. Active participation in other research therapy for cardiovascular repair/regeneration.
  15. Any medical condition that would affect the investigator's ability to evaluate the subject's condition or could compromise the subject's safety.
  16. Any condition that, in the judgment of the investigator, would prohibit the subject from participating in the study.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01076920


Locations
France
University Hospital (Rangueil)
Toulouse, France, 31059
Sponsors and Collaborators
University Hospital, Toulouse
French Blood Establishment (Midi-Pyrénées)
Nantes University Hospital
Ministry of Health, France
Investigators
Principal Investigator: jerome RONCALLI, MD, PhD University Hospital Of TOULOUSE
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Hospital, Toulouse
ClinicalTrials.gov Identifier: NCT01076920     History of Changes
Other Study ID Numbers: 0505008
First Posted: February 26, 2010    Key Record Dates
Last Update Posted: September 19, 2014
Last Verified: September 2014

Additional relevant MeSH terms:
Ischemia
Myocardial Ischemia
Coronary Artery Disease
Ventricular Dysfunction
Ventricular Dysfunction, Left
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases